Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Background: Oesophageal squamous cell carcinoma (OSCC) has a very poor prognosis, which is largely due to late diagnosis. Successful early detection strategies will require identification of ...

Abstract Spontaneous remission in patients with various cancers has been reported. Some patients with adult T-cell leukemia–lymphoma (ATL) have experienced spontaneous remission, although the ...